{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:18:57Z","timestamp":1787019537883,"version":"build-2736575974"},"reference-count":44,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors (TKIs) imatinib mesylate and nilotinib represents a successful application of molecularly targeted anticancer therapy. However, the effect of TKIs on leukemic stem cells remains incompletely understood. On the basis of a statistical modeling approach that used the 10-year imatinib mesylate treatment response of patients with CML and a patient cohort receiving first-line nilotinib therapy, we found that successful long-term therapy results in a triphasic exponential decline of BCR-ABL1 transcripts in many patients. Within our framework, the first slope of \u22120.052 \u00b1 0.018 (imatinib mesylate) and \u22120.042 \u00b1 0.015 (nilotinib) per day represents the turnover rate of leukemic differentiated cells, whereas the second slope of \u22120.0057 \u00b1 0.0038 (imatinib mesylate) and \u22120.0019 \u00b1 0.0013 (nilotinib) per day represents the turnover rate of leukemic progenitor cells. The third slope allows an inference of the behavior of immature leukemic cells, potentially stem cells. This third slope is negative in most patients, positive in others, and not observable in some patients. This variability in response may be because of insufficient follow-up, missing data, disease heterogeneity, inconsistent compliance to drug, or acquired resistance. Our approach suggests that long-term TKI therapy may reduce the abundance of leukemic stem cells in some patients.<\/jats:p>","DOI":"10.1182\/blood-2011-02-339267","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T20:24:04Z","timestamp":1307564644000},"page":"1622-1631","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":61,"title":["Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells"],"prefix":"10.1182","volume":"118","author":[{"given":"Min","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quintas-Cardama","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chani","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, SA Pathology, and University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, SA Pathology, and University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, SA Pathology, and University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111808511175200_B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"14","key":"2019111808511175200_B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808511175200_B3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111808511175200_B4","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111808511175200_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"ea. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract].","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111808511175200_B6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808511175200_B7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111808511175200_B8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"2019111808511175200_B9","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111808511175200_B10","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy.","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"7046","key":"2019111808511175200_B11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia.","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"10","key":"2019111808511175200_B12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"key":"2019111808511175200_B13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.bjc.6603604","article-title":"The long-term response to imatinib treatment of CML.","volume":"96","author":"Michor","year":"2007","journal-title":"Br J Cancer"},{"issue":"11","key":"2019111808511175200_B14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111808511175200_B15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111808511175200_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1102.1102","article-title":"The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, and any relapses occur early [abstract].","volume":"112","author":"Ross","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111808511175200_B17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.seminhematol.2010.06.007","article-title":"Practical considerations for monitoring patients with chronic myeloid leukemia.","volume":"47","author":"Branford","year":"2010","journal-title":"Semin Hematol"},{"issue":"3","key":"2019111808511175200_B18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates.","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"issue":"2","key":"2019111808511175200_B19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","article-title":"Do we have to kill the last CML cell?","volume":"25","author":"Ross","year":"2011","journal-title":"Leukemia"},{"key":"2019111808511175200_B20","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"issue":"7","key":"2019111808511175200_B21","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response.","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"14","key":"2019111808511175200_B22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5584","key":"2019111808511175200_B23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1126\/science.1070919","article-title":"Stochastic gene expression in a single cell.","volume":"297","author":"Elowitz","year":"2002","journal-title":"Science"},{"issue":"9","key":"2019111808511175200_B24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng1616","article-title":"Contributions of low molecule number and chromosomal positioning to stochastic gene expression.","volume":"37","author":"Becskei","year":"2005","journal-title":"Nat Genet"},{"issue":"6","key":"2019111808511175200_B25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrg1615","article-title":"Stochasticity in gene expression: from theories to phenotypes.","volume":"6","author":"Kaern","year":"2005","journal-title":"Nat Rev Genet"},{"issue":"5892","key":"2019111808511175200_B26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1158013","article-title":"Variability and robustness in T cell activation from regulated heterogeneity in protein levels.","volume":"321","author":"Feinerman","year":"2008","journal-title":"Science"},{"issue":"19","key":"2019111808511175200_B27","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"issue":"51","key":"2019111808511175200_B28","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.","volume":"103","author":"Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7330","key":"2019111808511175200_B29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature09733","article-title":"Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.","volume":"469","author":"Notta","year":"2011","journal-title":"Nature"},{"issue":"7330","key":"2019111808511175200_B30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature09650","article-title":"Genetic variegation of clonal architecture and propagating cells in leukaemia.","volume":"469","author":"Anderson","year":"2011","journal-title":"Nature"},{"issue":"5","key":"2019111808511175200_B31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"2019111808511175200_B32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.leu.2402678","article-title":"Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.","volume":"16","author":"Dorsey","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2019111808511175200_B33","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111808511175200_B34","first-page":"1168","article-title":"Expression of costimulatory molecules in human leukemias.","volume":"10","author":"Hirano","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"2019111808511175200_B35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"2019111808511175200_B36","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Considerations for targeting malignant stem cells in leukemia: chronic myeloid leukemia.","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"issue":"11","key":"2019111808511175200_B37","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111808511175200_B38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"2019111808511175200_B39","first-page":"7056","article-title":"Inference of imatinib (IM) effects on leukemic stem cell (SC) compartment via mathematical modeling of IRIS treatment response data [abstract].","author":"Bottino","year":"2009","journal-title":"ASCO Meeting Abstracts"},{"issue":"7","key":"2019111808511175200_B40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.leu.2403752","article-title":"Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.","volume":"19","author":"Lange","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"2019111808511175200_B41","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"32","key":"2019111808511175200_B42","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808511175200_B43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.leukres.2007.06.008","article-title":"Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.","volume":"32","author":"Alimena","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2019111808511175200_B44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","article-title":"Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.","volume":"130","author":"Angstreich","year":"2005","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1622\/1346415\/zh803211001622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1622\/1346415\/zh803211001622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T19:53:53Z","timestamp":1592596433000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/6\/1622\/29124\/Dynamics-of-chronic-myeloid-leukemia-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-339267","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,11]]}}}